Leerink Partnrs Issues Optimistic Estimate for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Leerink Partnrs boosted their FY2024 earnings estimates for shares of Hims & Hers Health in a research report issued on Tuesday, October 29th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.23 per share for the year, up from their prior estimate of $0.22. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s FY2027 earnings at $0.91 EPS.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same period last year, the business posted ($0.03) EPS. The company’s revenue was up 51.8% on a year-over-year basis.

Several other analysts have also recently issued reports on HIMS. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. Truist Financial upped their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. TD Cowen boosted their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Bank of America lifted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Moderate Buy” and a consensus target price of $20.21.

Hims & Hers Health Trading Down 14.3 %

HIMS opened at $19.06 on Thursday. Hims & Hers Health has a twelve month low of $5.76 and a twelve month high of $25.74. The firm has a market cap of $4.09 billion, a price-to-earnings ratio of 238.25 and a beta of 1.06. The company has a fifty day simple moving average of $17.89 and a 200 day simple moving average of $18.00.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 2,334 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total value of $40,378.20. Following the completion of the sale, the insider now directly owns 164,475 shares in the company, valued at $2,845,417.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $16.47, for a total value of $3,110,985.36. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $551,777.94. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Soleil Boughton sold 2,334 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20. Following the sale, the insider now directly owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 858,665 shares of company stock worth $15,148,890 over the last three months. Corporate insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its position in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC raised its holdings in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares during the period. CWM LLC raised its holdings in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health in the second quarter worth about $111,000. Finally, Amalgamated Bank increased its position in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after acquiring an additional 2,354 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.